Vorasidenib, an oral brain-penetrant inhibitor of mutant IDH1 and IDH2 enzymes ... manuscript preparation was provided by a professional medical writer funded by the sponsor.

This IDH1 mutation is unique to gliomas and leads to the creation of novel proteins called neo-epitopes. Michael Platten, from the German Cancer Research Center, has been working for years to ...

1 The most common variant in gliomas causes an amino acid change at position 132 of the IDH1 protein (IDH1 R132H), which results in a new, oncogenic enzymatic activity: mutant IDH (mIDH ...

M.D., senior medical director at Servier, noted in an interview with Fierce Pharma ahead of Tuesday’s FDA decision. Before Voranigo, Servier already has the IDH1 inhibitor Tibsovo and the IDH2 ...

of the Drexel University School of Medicine. At that point, the patient underwent “surgical debulking” of his tumor. The pathology specimen confirmed the diagnosis of GBM and that the patient’s tumor ...

Among the 1000 patients with high-risk MDS, 32 (3%) had an IDH1 mutation, and among the 1300 patients with low-risk disease, 2.8% (n=37) had an IHD1 mutation.The prevalence of IDH1 mutations among ...

Dr. Bobby Mukkamala, a popular Flint doctor, said he had a one percent chance of dying after a cancer diagnosis in the fall.

Evidence-based recommendations on ivosidenib (Tibsovo) for treating locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation in adults ... Non-NHS organisations can contact medical ...